1887

Abstract

We report the range of minimum inhibitory concentrations for six antimicrobial drugs in 228 clinical (MTB) isolates from three distinct groups of patients (unselected patients, patients at high risk of drug-resistant TB and HIV-positive patients) in Lima, Peru. These data highlight the challenges of and discriminatory characteristics required for MTB drug susceptibility testing.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000534
2017-07-01
2020-01-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/7/1023.html?itemId=/content/journal/jmm/10.1099/jmm.0.000534&mimeType=html&fmt=ahah

References

  1. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012;90:693–698 [CrossRef][PubMed]
    [Google Scholar]
  2. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010;54:1484–1491 [CrossRef][PubMed]
    [Google Scholar]
  3. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963;29:565–578[PubMed]
    [Google Scholar]
  4. Hoffner SE, Salfinger M. Ad fontes!. Int J Tuberc Lung Dis 2010;14:260[PubMed]
    [Google Scholar]
  5. Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 2009;37:296–305 [CrossRef][PubMed]
    [Google Scholar]
  6. Moore DAJ, Evans CAW, Gilman RH, Caviedes L, Coronel J et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med Overseas Ed 2006;355:1539–1550 [CrossRef]
    [Google Scholar]
  7. Leonard B, Coronel J, Siedner M, Grandjean L, Caviedes L et al. Inter- and intra-assay reproducibility of microplate Alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2008;46:3526–3529 [CrossRef][PubMed]
    [Google Scholar]
  8. Updated interim critical concentrations for first-line and second-line DST 2012; WHO Global TB Programme. www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table_1st%20and%202nd%20line%20drugs.pdf accessed Sept 2016
  9. NCCLS Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, Approved Standard. NCCLS document M24-A [ISBN 1-56238-500-3]. Wayne, PA: 2003
    [Google Scholar]
  10. Kam KM, Sloutsky A, Yip CW, Bulled N, Seung KJ et al. Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010;14:282–288[PubMed]
    [Google Scholar]
  11. Madison B, Robinson-Dunn B, George I, Gross W, Lipman H et al. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002;40:3976–3979 [CrossRef][PubMed]
    [Google Scholar]
  12. Horne DJ, Pinto LM, Arentz M, Lin SY, Desmond E et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol 2013;51:393–401 [CrossRef][PubMed]
    [Google Scholar]
  13. Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009;64:786–793 [CrossRef][PubMed]
    [Google Scholar]
  14. Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G et al. Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10. Clin Microbiol Infect 2015;21:148.e5–14148 [CrossRef][PubMed]
    [Google Scholar]
  15. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. 2016;www.eucast.org
  16. Sheen P, Couvin D, Grandjean L, Zimic M, Dominguez M et al. Genetic diversity of Mycobacterium tuberculosis in Peru and exploration of phylogenetic associations with drug resistance. PLoS One 2013;8:e6587312 [CrossRef][PubMed]
    [Google Scholar]
  17. Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M et al. Multidrug-resistant tuberculosis around the world: what progress has been made?. Eur Respir J 2015;45:150–160 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000534
Loading
/content/journal/jmm/10.1099/jmm.0.000534
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error